The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout. Energy and pharma names account for the top four holdings, combining for 25.96% of net assets. With HDV up 19.66% year-to-date and yielding roughly 3%, I want to know whether the checks these four giants send to BlackRock are actually safe.
The Four Dividends Powering HDV
| Holding | Weight | Yield | Streak |
|---|---|---|---|
| Exxon Mobil (NYSE:XOM | XOM Price Prediction) | 8.42% | 2.65% | 43 yrs |
| Chevron (NYSE:CVX) | 6.42% | 3.67% | 38+ yrs |
| Johnson & Johnson (NYSE:JNJ) | 5.68% | 2.06% | 64 yrs (King) |
| AbbVie (NYSE:ABBV) | 5.44% | 2.80% | 13 yrs standalone |
Exxon: The Cleanest Balance Sheet in the Group
Chevron: Hess Cash Flow Reset the Math
Johnson & Johnson: The Dividend King Earns Its Crown
AbbVie: Growing but Leveraged
The Verdict on HDV’s Income Engine
Contact [email protected] for any questions or corrections.








